These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17999663)

  • 61. Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.
    Chen A; Campeau LC; Cauchon E; Chefson A; Ducharme Y; Dubé D; Falgueyret JP; Fournier PA; Gagné S; Grimm E; Han Y; Houle R; Huang JQ; Lacombe P; Laliberté S; Lévesque JF; Liu S; MacDonald D; Mackay B; McKay D; Percival MD; Regan C; Regan H; St-Jacques R; Toulmond S
    Bioorg Med Chem Lett; 2011 Jul; 21(13):3970-5. PubMed ID: 21621998
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin.
    Göschke R; Stutz S; Rasetti V; Cohen NC; Rahuel J; Rigollier P; Baum HP; Forgiarini P; Schnell CR; Wagner T; Gruetter MG; Fuhrer W; Schilling W; Cumin F; Wood JM; Maibaum J
    J Med Chem; 2007 Oct; 50(20):4818-31. PubMed ID: 17824679
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Design and optimization of new piperidines as renin inhibitors.
    Corminboeuf O; Bezençon O; Grisostomi C; Remeň L; Richard-Bildstein S; Bur D; Prade L; Hess P; Strickner P; Fischli W; Steiner B; Treiber A
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6286-90. PubMed ID: 20843686
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines.
    Chen A; Cauchon E; Chefson A; Dolman S; Ducharme Y; Dubé D; Falgueyret JP; Fournier PA; Gagné S; Gallant M; Grimm E; Han Y; Houle R; Huang JQ; Hughes G; Jûteau H; Lacombe P; Lauzon S; Lévesque JF; Liu S; Macdonald D; Mackay B; McKay D; Percival MD; St-Jacques R; Toulmond S
    Bioorg Med Chem Lett; 2011 Jul; 21(13):3976-81. PubMed ID: 21641209
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The discovery of small molecule inhibitors of neutral endopeptidase. Structure-activity studies on functionalized glutaramides.
    Maw GN; Stobie A; Planken S; Pryde DC; Sanderson V; Platts MY; Corless M; Stacey P; Wayman C; Van Der Graaf P; Kohl C; Coggon S; Beaumont K
    Chem Biol Drug Des; 2006 Jan; 67(1):74-7. PubMed ID: 16492151
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In brief: Another three-drug combination for hypertension.
    Med Lett Drugs Ther; 2011 Apr; 53(1361):28. PubMed ID: 21464804
    [No Abstract]   [Full Text] [Related]  

  • 67. Discovery of highly potent renin inhibitors potentially interacting with the S3' subsite of renin.
    Sun X; Wen X; Chen YY; Shi C; Gao C; Wu Y; Wang LJ; Yang XH; Sun H
    Eur J Med Chem; 2015 Oct; 103():269-88. PubMed ID: 26363506
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Design and synthesis of nonpeptide peptidomimetic inhibitors of renin.
    Smith AB; Akaishi R; Jones DR; Keenan TP; Guzman MC; Holcomb RC; Sprengeler PA; Wood JL; Hirschmann R; Holloway MK
    Biopolymers; 1995; 37(1):29-53. PubMed ID: 7880965
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New renin inhibitors with hydrophilic C-terminus.
    Paruszewski R; Jaworski P; Winiecka I; Tautt J; Dudkiewicz J
    Pharmazie; 1999 Feb; 54(2):102-6. PubMed ID: 10084156
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Design and optimization of novel (2S,4S,5S)-5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxy-2-isopropylhexanamides as renin inhibitors.
    Nakamura Y; Sugita C; Meguro M; Miyazaki S; Tamaki K; Takahashi M; Nagai Y; Nagayama T; Kato M; Suemune H; Nishi T
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4561-6. PubMed ID: 22726934
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alice Huxley and Nick Miles of Speedel on the company's pipeline and future plans. Interview by Christopher Watson and Stephen Carney.
    Huxley A; Miles N
    Drug Discov Today; 2005 Jul; 10(13):881-3. PubMed ID: 15993805
    [No Abstract]   [Full Text] [Related]  

  • 72. Renin excess after renin inhibition: malefactor or innocent bystander?
    Re RN; Messerli FH
    Int J Clin Pract; 2007 Sep; 61(9):1427-9. PubMed ID: 17686087
    [No Abstract]   [Full Text] [Related]  

  • 73. Braces for the peptide backbone: insights into structure-activity relationships of protease inhibitor mimics with locked amide conformations.
    Tischler M; Nasu D; Empting M; Schmelz S; Heinz DW; Rottmann P; Kolmar H; Buntkowsky G; Tietze D; Avrutina O
    Angew Chem Int Ed Engl; 2012 Apr; 51(15):3708-12. PubMed ID: 22374650
    [No Abstract]   [Full Text] [Related]  

  • 74. Discovery of non-peptidic P2-P3 butanediamide renin inhibitors with high oral efficacy.
    Simoneau B; Lavallée P; Anderson PC; Bailey M; Bantle G; Berthiaume S; Chabot C; Fazal G; Halmos T; Ogilvie WW; Poupart MA; Thavonekham B; Xin Z; Thibeault D; Bolger G; Panzenbeck M; Winquist R; Jung GL
    Bioorg Med Chem; 1999 Mar; 7(3):489-508. PubMed ID: 10220035
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog.
    Boyd SA; Fung AK; Baker WR; Mantei RA; Stein HH; Cohen J; Barlow JL; Klinghofer V; Wessale JL; Verburg KM
    J Med Chem; 1994 Sep; 37(19):2991-3007. PubMed ID: 7932521
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Design, synthesis and biological evaluation of renin inhibitors guided by simulated annealing of chemical potential simulations.
    Cloudsdale IS; Dickson JK; Barta TE; Grella BS; Smith ED; Kulp JL; Guarnieri F; Kulp JL
    Bioorg Med Chem; 2017 Aug; 25(15):3947-3963. PubMed ID: 28601508
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Blood substitutes based on nanobiotechnology.
    Chang TM
    Trends Biotechnol; 2006 Aug; 24(8):372-7. PubMed ID: 16815577
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacometrics and the transition to model-based development.
    Grasela TH; Dement CW; Kolterman OG; Fineman MS; Grasela DM; Honig P; Antal EJ; Bjornsson TD; Loh E
    Clin Pharmacol Ther; 2007 Aug; 82(2):137-42. PubMed ID: 17632539
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Design and discovery in the development of long-acting renin inhibitors.
    Veber DF; Payne LS; Williams PD; Perlow DS; Lundell GF; Gould NP; Siegl PK; Sweet CS; Freidinger RM
    Biochem Soc Trans; 1990 Dec; 18(6):1291-4. PubMed ID: 2088926
    [No Abstract]   [Full Text] [Related]  

  • 80. Peptide Mimetics: Fast-Forward Look.
    Gurwitz D
    Drug Dev Res; 2017 Sep; 78(6):231-235. PubMed ID: 28833328
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.